🏢 官网IRZTSDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 04:15:00(美东 10-08 16:15)时区推断·⟳ 抓取 04:18:00回填·⚡ 决策 10-09 04:19:22·18.7 天前
硕腾(Zoetis)宣布2026年第四季度每股0.53美元季度股息
季度股息宣告是高度程式化、市场已充分预期的例行公司行动,金额相对市值极小,无指引、盈利或订单层面的新增信息,不产生正期望交易机会。
📄 原文ZTS↗ 原文
Zoetis Declares Fourth Quarter 2026 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 p…
不做 Zoetis Inc.(ZTS.US)
常规季度股息宣告,无超预期增量、规模相对市值极小且已被市场预期,不构成短线交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
硕腾宣布每股0.53美元的常规季度股息,支付与登记日均为例行安排;此类宣告不含盈利或基本面增量,预期早已反映,不构成可交易催化。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 high ↗
关键理由
- 季度常规股息是可预期的资本回报,规模相对约数百亿美元市值微不足道,无法驱动重定价。
主要风险
- 若0.53美元相对此前季度实为上调,可能带来轻微正面情绪,但当前无证据表明超出市场预期,不足以改变结论。
先例如何影响了这次决策
对本次决策的影响:确认该事件缺乏增量edge,支持AVOID,不产生任何仓位。
方向:常规季度股息宣告历史上通常对股价无显著方向性影响,多为中性事件。
涨幅量级:无高相似对齐先例用于校准幅度,且事件本身不具交易价值,无需设定tp/sl。
形态:例行股息宣告未见系统性见光死或上涨模式,因股息已被预期,除息前后主要为机械除权调整。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`zoetis dividend december 1 2026 record october 30 | zoetis zts fourth quarter 2026 dividend $0.53 per share declared`;结构化索引覆盖完整 72 小时;旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整),返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选,不能据此证明消息首发或不是重复;按当前事件继续正常研判。"}
原文全文
展开原文 · 3,033 字
PARSIPPANY, N.J.--(BUSINESS WIRE)--
The Board of Directors of
Zoetis Inc.
(NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Friday, October 30, 2026.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness supporting veterinarians, livestock producers and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit
Zoetis.com
.
DISCLOSURE NOTICES
Forward-Looking Statements
: This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at
www.sec.gov
,
www.zoetis.com
, or on request from Zoetis.
ZTS-COR
ZTS-IR
ZTS-FIN
Media Contacts
:
Jennifer Albano
1-862-399-0810 (o)
jennifer.albano@zoetis.com
Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com
Investor Contacts
:
Mathieu Aussermeier
1-862-460-0181 (o)
mathieu.aussermeier@zoetis.com
Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com
Source: Zoetis Inc.
The Board of Directors of
Zoetis Inc.
(NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Friday, October 30, 2026.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness supporting veterinarians, livestock producers and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit
Zoetis.com
.
DISCLOSURE NOTICES
Forward-Looking Statements
: This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at
www.sec.gov
,
www.zoetis.com
, or on request from Zoetis.
ZTS-COR
ZTS-IR
ZTS-FIN
Media Contacts
:
Jennifer Albano
1-862-399-0810 (o)
jennifer.albano@zoetis.com
Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com
Investor Contacts
:
Mathieu Aussermeier
1-862-460-0181 (o)
mathieu.aussermeier@zoetis.com
Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com
Source: Zoetis Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
7324a878c1· 2026-10-09 04:19 · doubao / doubao-seed-evolving-latest-version · 策略包d5018cb8913f当前